PT - JOURNAL ARTICLE AU - Waldron, Kelly AU - Ramnarine, Emma AU - Hartman, Jeffrey TI - 2015/2016 Quality Risk Management Benchmarking Survey AID - 10.5731/pdajpst.2017.007526 DP - 2017 Jan 01 TA - PDA Journal of Pharmaceutical Science and Technology PG - pdajpst.2017.007526 4099 - http://journal.pda.org/content/early/2017/05/15/pdajpst.2017.007526.short 4100 - http://journal.pda.org/content/early/2017/05/15/pdajpst.2017.007526.full AB - This paper investigates the concept of Quality Risk Management (QRM) maturity as it applies to the pharmaceutical and biopharmaceutical industries, using the results and analysis from a QRM benchmarking survey conducted in 2015 and 2016. QRM maturity can be defined as the effectiveness and efficiency of a quality risk management program, moving beyond 'check-the-box' compliance with guidelines such as ICH Q9 Quality Risk Management, to explore the value QRM brings to business and quality operations. While significant progress has been made towards full adoption of quality risk management principles and practices across industry, the full benefits of QRM have not yet been fully realized. The results of the QRM Benchmarking Survey indicate that the pharmaceutical and biopharmaceutical industries are approximately halfway along the journey towards full QRM maturity.